Decreasing systemic toxicity via transdermal delivery of anticancer drugs

Jia You Fang, Pei Feng Liu, Chun Ming Huang

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


When used at a high dose, many anticancer drugs produce undesirable side effects including hepatotoxicity. Transdermal delivery bypasses first-pass metabolism, allowing the use of a lower dose of drug while decreasing systemic toxicity. In this review, we summarize various advanced technologies for improving anticancer drug delivery via the skin. This technology is discussed in the context of three anticancer drugs, 5-fluorouracil (5-FU), methotrexate (MTX) and 5-aminolevulinic acid (5-ALA). The use of a erbium:YAG (Er:YAG) laser for transdermal delivery of anticancer drugs is specifically highlighted in this review.

Original languageEnglish
Pages (from-to)592-597
Number of pages6
JournalCurrent Drug Metabolism
Issue number7
StatePublished - 2008


  • Anticancer drugs
  • Laser
  • Toxicity
  • Transdermal delivery


Dive into the research topics of 'Decreasing systemic toxicity via transdermal delivery of anticancer drugs'. Together they form a unique fingerprint.

Cite this